Navigation Links
Does Anti-TNF Therapy Control Ankylosis ?

Arthritis is a condition resulting from inflammation of joints. It causes swelling and pain resulting in limited movement.//

Spondylarthritis (SpA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), and inflammatory bowel disease are all associated rheumatic diseases collectively known as "spondyloarthropathies". Aside from chronic inflammation, these conditions are all characterized by ankylosis, stiffness and fusion of bone in the spine and peripheral joints. Ankylosis is an incapacitating condition that ultimately results in loss of spinal mobility and function severely affecting a person's quality of life.

Currently, inhibition of tumor necrosis factor á (TNFá) is the most effective strategy for controlling the painful symptoms of SpA and slowing vertebral joint destruction. But does anti-TNF therapy do anything to reduce the incidence or severity of ankylosis?

To answer this critical question, a quartet of researchers led by Dr. Frank P. Luyten, Division of Rheumatology, University Hospitals, Leuven, Belgium, tested the effectiveness of etanercept, an established TNF receptor, on animal models of arthritis.

Their findings, highlighted in the February 2007 issue of Arthritis & Rheumatism (http://www.interscience.wiley.com/journal/arthritis), cast doubts on the feasibility of preventing joint and spine ankylosis with anti-TNF strategies while shedding light on the process of SpA.

A sample of male mice with spontaneous arthritis were caged together and observed from the age of 10 weeks. From week 12 to week 25, the mice were treated twice weekly with etanercept, in a strength comparable to standard dosage for human patients, or a placebo. Mice were also scored twice weekly for signs of arthritis, including cartilage formation, bone formation, and joint ankylosis. The mice were killed at age 25 weeks, autopsied, and analyzed, through cell population staining, for the presence of TNFá.

In a complementary experiment, another sample of mice was induced with arthritis, using methylated bovine serum albumin. Four days later, these mice were given a single injection of etanercept. Three days later, on day seven, they were killed. Signs of arthritis were assessed and graded for cartilage destruction and bone erosion.

For the mice with induced arthritis, etanercept had a significant impact on disease severity, inhibiting inflammation and cartilage and bone destruction. For the mice with spontaneous arthritis, however, etanercept proved no more effective than placebo at inhibiting new cartilage or bone formation or ankylosis. What's more, TNFá-positive cells were observed in the joint capsule, adjacent blood vessels and in new cartilage.

"Our observations strengthen our hypothesis that new bone formation in SpA is clinically relevant and largely independent of inflammation," Dr. Luyten states. "Long-term results from clinical trials are required to corroborate this hypothesis in patients with SpA," he acknowledges, "and to define whether the process of ankylosis should become a separate therapeutic target."



Source-Eurekalert
RI
'"/>




Related medicine news :

1. Cancer Doctors Okays Controversial Prostate Therapy
2. Consensus on "Combination Therapy" for Breast Cancer
3. Gene Therapy shows promise in treating Hemophilia
4. "Make AIDS Therapy affordable" - Physicians demand
5. Hormone replacement Therapy a headache
6. Simple Therapy
7. Therapy for stopping the spread of cancer cells
8. Gene Therapy Destroys Pancreatic Cancer Cells
9. Letrozole Beats Tamoxifen in Breast Cancer Therapy
10. Garlic Supplements Impede HIV Therapy
11. Gene Therapy For Cystic Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/19/2017)... Boston,MA (PRWEB) , ... February 19, 2017 , ... ... software solutions for connected home healthcare, will join forces with Healthwise ® ... and education. Healthwise, the industry leader in evidence-based health education, technology and ...
(Date:2/18/2017)... ... February 17, 2017 , ... Butler Mobility invited Ken Matthews ... and other Butler products. Ken was impressed with the safety and reliability of ... the product on his show. This endorsement by Ken Matthews can be heard ...
(Date:2/18/2017)... ... February 18, 2017 , ... ProParagraph Fashion Volume ... Studios ’ ProParagraph Fashion Volume 2 for all multi-line FCPX project needs. ... can pick and choose from hand-crafted trend-setting designs with smooth animations that will ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... kept pace. Enovate Medical has introduced an innovative workstation designed to reduce nursing ... nurses, the Encore Mobile EHR Workstation offers a lightweight, highly mobile, multi-functional alternative ...
(Date:2/17/2017)... ... February 17, 2017 , ... For the first time, ... to the exhibit floor for the 2017 HIMSS Conference & Exhibition ... 19–23, 2017, more than 40,000 healthcare industry professionals are expected at the conference, ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... --  Orion Health ™ announced today the ... to the Amazon Web Services, Inc. (AWS) Cloud. ... records globally. "We are impressed by Orion ... on modern, scalable technology," said Steve Halliwell , ... Cloud gives healthcare companies a powerful tool to enable ...
(Date:2/20/2017)... , Feb. 20, 2017  Today from HIMSS17, ... image management suite, announced the launch of  Ambra ... medical imaging. Built around modern, RESTful web-services, this is ... imaging. With these new APIs, IT departments ... and imaging data into other applications such as population ...
(Date:2/20/2017)... Research and Markets has announced the ... to 2022" report to their offering. ... An increasing number ... rising adoption of tension free repair procedures and increasing demand ... repair devices global market. However, Inconsistent reimbursement and the high ...
Breaking Medicine Technology: